Search Results
Your search for this matches 25378 pages
Showing 24101 - 241502014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, FRS, May-Britt Moser, PhD, and Edvard I. Moser, PhD
The Nobel Assembly at Karolinska Institutet has awarded the 2014 Nobel Prize in Physiology or Medicine to John O’Keefe, FRS, and to May-Britt Moser, PhD, and Edvard I. Moser, PhD, for their discoveries of cells that constitute a positioning system in the brain. This “inner GPS”...
No Increased Risk of Ovarian Cancer With Perineal Powder Use
Perineal powder use has been associated with increased risk of ovarian cancer in case-control studies and with increased risk of serous invasive ovarian cancer in a cohort study. In a large cohort study reported in the Journal of the National Cancer Institute, Houghton et al found no significant...
Study Finds Increase in Colonoscopy Rates Has Lead to Overuse
A retrospective study led by researchers at Brigham and Women's Hospital has found an overuse of colonoscopies for colorectal cancer screening and surveillance. The study demonstrated that endoscopists commonly recommended shorter follow-up intervals than established guidelines support, and these...
FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme Therapeutics is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and...
Comorbidity Associated With Shorter Overall Survival but Not With Time to Relapse or Toxicity in Older Women on Adjuvant Chemotherapy
In the Cancer and Leukemia Group B (CALGB) 70103 study, comorbidity was associated with shorter overall survival among older women with early-stage breast cancer and good functional status receiving adjuvant chemotherapy. “The presence of four or more conditions appeared to be a threshold for ...
FDG-PET Is Less Specific in Diagnosing Lung Cancer in Areas With Endemic Infectious Lung Disease
Although positron-emission tomography (PET) combined with 18F–fluorodeoxyglucose (FDG) is recommended for the noninvasive diagnosis of pulmonary nodules suspicious for lung cancer, in populations with endemic infectious lung disease, FDG-PET may not accurately identify malignant lesions. An...
Enhanced Benefit Shown With FOLFIRI/Ziv-Aflibercept in Subset of Patients With Metastatic Colorectal Cancer
The survival benefit demonstrated in the VELOUR study for FOLFIRI (irinotecan, fluorouracil [5-FU], leucovorin) plus ziv-aflibercept (Zaltrap) vs FOLFIRI plus placebo in metastatic colorectal cancer patients who had disease progression on oxaliplatin-based chemotherapy persisted beyond median...
Researchers Discover Genetic Variant That Can Predict Aggressive Prostate Cancer at Diagnosis
Researchers at The University of Texas MD Anderson Cancer Center have identified a biomarker adjacent to the KLK3 gene that can predict which prostate cancer patients with a Gleason score of 7 will have a more aggressive form of cancer. The findings by He et al, published in Clinical Cancer...
FDA Grants Breakthrough Therapy Designation to AP26113 for ALK-Positive NSCLC
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Ariad Pharmaceutical’s investigational agent AP26113 for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who are resistant to crizotinib...
Sex Steroid Hormones May Play a Role in the Development of Aggressive Prostate Cancer
Men with higher estradiol-to-testosterone ratios had a substantially reduced risk of aggressive prostate cancer, whereas men with higher ratios of 2-hydroxyestrone to 16α-hydroxyestrone had an increased risk of such cancer, according to the study findings presented by Black et al in Cancer...
Chemoradiotherapy vs Radiotherapy Alone Linked to Increased Risk of Subsequent Malignancies in Long-Term Survivors of Hereditary Retinoblastoma
Increased risk of subsequent malignant neoplasms has been reported in hereditary retinoblastoma survivors after radiotherapy. In a study reported in Journal of Clinical Oncology, Wong et al found that chemotherapy plus radiotherapy was associated with increased risk of subsequent malignant...
ESMO 2014: Abiraterone Plus Prednisone Significantly Improves Overall Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...
PSA Bounce After Radiotherapy May Be Associated With Outcomes in Patients With Prostate Cancer
A temporary rise in prostate-specific antigen (PSA) scores after radiotherapy may have an association with outcomes in patients with prostate cancer, according to the study findings presented by Naghavi et al in the International Journal of Clinical Oncology. Experiencing a PSA bounce was...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
Next-Generation HPV Vaccine May Prevent 90% of Cervical Cancer Cases Worldwide
A study of a nine-valent human papillomavirus (HPV) vaccine that provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, has found it to be highly safe and efficacious. If vaccination programs with this new-generation vaccine are effectively implemented, approximately 90% of...
ESMO 2014: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma
The monoclonal antibody nivolumab achieved superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab (Yervoy), according to preliminary data from a phase III trial presented at the ESMO 2014...
ESMO 2014: Lung Cancer Vaccine Fails to Improve Survival in Surgically Resected Non–Small Cell Lung Cancer
The MAGRIT trial showed disappointing results for a developmental vaccine called MAGE-3 in patients with non–small cell lung cancer (NSCLC) who had undergone surgical resection. This is the largest vaccine trial conducted in lung cancer, and investigators hoped that an immunotherapy approach...
ESMO 2014: Phase III Study Confirms Regorafenib’s Survival Benefit in Metastatic Colorectal Cancer
The phase III CONCUR trial of regorafenib (Stivarga) monotherapy in Asian patients with previously treated metastatic colorectal cancer confirmed the overall survival benefit seen in the previous CORRECT trial and in an exploratory analysis suggested the benefit is substantial in patients not...
ESMO 2014: BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials
For advanced/metastatic melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to studies presented at the ESMO 2014 Congress that demonstrated improved progression-free and overall survival for regimens combining a BRAF inhibitor with an inhibitor of the...
Study Finds Association Between Increased Esophageal COX-2 Expression and Barrett’s Esophagus, Obesity, and Smoking
Elevated esophageal mucosa cyclooxygenase-2 (COX-2) levels appear to be associated with the presence of Barrett’s esophagus as well as high waist-to-hip ratios and current tobacco smoking, according to the results of a study reported by Nguyen et al in Digestive Diseases & Sciences. These ...
ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer
For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...
ESMO 2014: Afatinib Improves Progression-Free Survival in Advanced Head and Neck Cancer
The tyrosine kinase inhibitor afatinib (Gilotrif) was significantly superior to methotrexate as second-line therapy in patients with advanced squamous cell carcinoma of the head and neck who progressed after platinum-based chemotherapy, according to results of the LUX-Head & Neck 1 trial. The...
ESMO 2014: Novel Oral Agent Treats Cancer-Related Cachexia in Non–Small Cell Lung Cancer
For the first time, studies show that a drug is effective in treating cancer-related cachexia. Oral anamorelin hydrochloride increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented at the ESMO...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer
In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...
Boost in Plasma Levels of Chain Amino Acids Is Associated With Increased Risk of Pancreatic Cancer
In a recent study reported in Nature Medicine, scientists from Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and the Harvard School of Public Health, among other institutions, investigated whether pancreatic ductal adenocarcinoma produces metabolic changes that can be...
Soy Intake May Adversely Affect Gene Expression in Early Breast Cancer
In a randomized study reported in the Journal of the National Cancer Institute, Shike et al found that soy supplementation resulting in high genistein levels was associated with overexpression of the tumorigenic growth factor receptor FGFR2 and genes that drive cell cycle and proliferation...
Meta-Analysis Shows No Overall Survival Benefit of Six vs Fewer Planned Cycles of First-Line Platinum-Based Chemotherapy in Advanced NSCLC
In a systematic review and meta-analysis of individual patient data reported in The Lancet Oncology, Rossi et al found no overall survival benefit with six vs fewer than six planned cycles of first-line platinum-based treatment in patients with advanced non–small cell lung cancer (NSCLC). A...
Continuous Lenalidomide/Dexamethasone Improves Progression-Free Survival in Transplant-Ineligible Patients With Myeloma
In the phase III FIRST trial reported in The New England Journal of Medicine, Benboubker et al found that continuous lenalidomide (Revlimid) plus dexamethasone significantly improved progression-free survival vs melphalan/prednisone/thalidomide (Thalomid) in transplant-ineligible myeloma patients....
Clinical Trials Investigate Treatment Options for Precursor Diseases to Multiple Myeloma
The availability of newer agents that have transformed treatment outcomes in multiple myeloma has naturally led to interest in studying these drugs earlier in precursor states, such as monoclonal gammopathy of undetermined significance and smoldering myeloma. Recent evidence suggests that this may...
Pazopanib Maintenance Improves Progression-Free Survival in Ovarian Cancer, but Benefit Limited to Non–East Asian Patients
In a phase III trial reported in the Journal of Clinical Oncology, du Bois et al found that maintenance therapy with the VEGFR and PDGFR inhibitor pazopanib (Votrient) significantly prolonged progression-free survival vs placebo in women with ovarian cancer without progression after first-line...
Patient Exhibits Involution of Eruptive Melanocytic Nevi on Combination BRAF and MEK Inhibitor Therapy
Eruptive melanocytic nevi are observed in patients receiving the multikinase inhibitor sorafenib (Nexavar) and the selective BRAF inhibitor vemurafenib (Zelboraf). In a case reported in JAMA Dermatology, Shen et al found that the addition of the MEK inhibitor cobimetinib to vemurafenib in a woman...
Pilot Study Evaluates Concurrent Use of Sunitinib and Radiation Therapy in Recurrent High-Grade Glioma
The combination of continuous daily-dosed sunitinib (Sutent) and hypofractionated stereotactic radiation therapy produced acceptable toxicity and “encouraging” 6-month progression-free survival in previously irradiated patients with recurrent high-grade glioma, according to the results...
Preclinical Study Identifies Potential Drug Combination for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Combining the molecular targeted drug ibrutinib (Imbruvica) with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to preclinical data presented at the American Association for Cancer Research...
Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma
In the phase III PANORAMA1 trial reported in The Lancet Oncology, San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple...
Preclinical Study Looks at RNA Polymerase I Inhibitor in Refractory AML and Multiple Myeloma
A laboratory study of the investigational drug CX-5461, which blocks the inhibition of RNA polymerase I transcription, has found that it prolonged survival in mouse models of highly aggressive acute myeloid leukemia (AML) and multiple myeloma refractory to standard therapy. In addition, the...
Tyrosine Kinase Inhibitors May Improve Treatment Outcomes in Children With Philadelphia Chromosome–Like ALL
Using genomic profiling and next-generation sequencing of patients with BCR-ABL1-like B-progenitor acute lymphoblastic leukemia (B-cell ALL) and Philadelphia chromosome–like ALL, researchers recently identified alterations targeting 18 kinase or cytokine receptor genes. They then determined...
Search for Effective Regimens in Elderly Patients With Hodgkin Lymphoma
As the U.S. population continues to age, oncologists will be faced with a growing number of elderly patients with Hodgkin lymphoma, but there is currently no consensus on how to treat this population. Regimens used to treat younger patients have too much toxicity for most older patients, and thus...
SMaRT Oncology-3 Trial Reports Collaborative Care Program Reduces Major Depression in Patients With Lung Cancer
In the SMaRT Oncology-3 study reported in The Lancet Oncology, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly reduced severity of depression compared with usual care in...
Integrated Collaborative Care Program Highly Successful in Treating Major Depression in Patients With Cancer
In a Scottish study (SMaRT Oncology-2) reported in The Lancet, Sharpe, Walker et al found that an integrated collaborative treatment program for depression (‘depression care for people with cancer’) was associated with significantly higher depression response and remission rates...
Second-Line Ramucirumab Plus Paclitaxel Improves Overall Survival in Patients With Advanced Gastric Cancer
The addition of the monoclonal antibody VEGFR-2 antagonist ramucirumab (Cyramza) to paclitaxel led to a statistically significant improvement in median overall survival in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma in a phase III trial, reported Wilke et al in ...
Para-Aortic Lymph Node Radiation Increases Risk of Diabetes in Hodgkin Lymphoma Survivors
Abdominal irradiation for childhood cancer has been associated with increased risk of diabetes. In a Dutch study reported in the Journal of Clinical Oncology, van Nimwegen and colleagues assessed the relationship between infradiaphragm radiotherapy and risk of diabetes in long-term survivors of...
Lymphatic Mapping Agent Receives Orphan Drug Designation for Head and Neck Cancers
Navidea Biopharmaceuticals, Inc, recently announced that technetium 99m tilmanocept (Lymphoseek Injection) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for use in sentinel lymph node detection in patients with cancer of the head and neck. The designation...
mTOR Inhibitor Ridaforolimus Shows Activity in Advanced Endometrial Cancer
The oral mTOR inhibitor ridaforolimus was modestly active and reasonably tolerated in women with recurrent or metastatic endometrial cancer, according to the results of a phase II study reported in Gynecologic Oncology. Tsoref et al suggested that it may prove to be an effective therapeutic...
Improved Outcomes in Myeloma With High-Dose Melphalan Plus Autologous Transplant and Lenalidomide Maintenance
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid)...
ASTRO: Analysis Finds Select Group of Stage IV Lung Cancer Patient Population Achieves Long-Term Survival After Aggressive Treatment
A large, international analysis of patients with stage IV non–small cell lung cancer (NSCLC) indicates that a patient’s overall survival rate can be related to factors including the timing of when metastases develop and lymph node involvement, and that aggressive treatment for low-risk...
ASTRO: Good Primary Tumor Control, Positive 5-Year Survival Rates for Lung Cancer Patients Who Receive Stereotactic Body Radiation Therapy
Patients with inoperable, early-stage lung cancer who receive stereotactic body radiation therapy have a 5-year survival rate of 40%, according to long-term results presented at the American Society for Radiation Oncology’s (ASTRO) 56th Annual Meeting (Abstract 56). Such a positive survival...
ASTRO: Long-Term Androgen-Deprivation Therapy Plus High-Dose Radiation Therapy Improves Biochemical Control and Survival Rates in Prostate Cancer
Prostate cancer patients who receive high-dose radiation therapy followed by a longer period of androgen-deprivation therapy have higher 5-year biochemical disease–free survival and overall survival rates compared to patients who receive high-dose radiation therapy and a shorter duration of...
Study Identifies Two Novel ALK Mutations Causing Lung Cancer Resistance to ALK Inhibitors
In a recent study investigating alectinib resistance in ALK-positive lung cancers, researchers identified two novel ALK mutations that are sensitive to ceritinib (Zykadia), a next-generation ALK tyrosine kinase inhibitor approved by the FDA earlier this year for advanced non–small cell lung...
Anti-CD19 CAR T-Cell Treatment Effective in Chemotherapy-Refractory B-Cell Malignancies
In a study reported in the Journal of Clinical Oncology, Kochenderfer et al found that single infusions of autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) produced responses in nearly all patients with chemotherapy-refractory CD19-positive B-cell malignancies, including...
